Please ensure Javascript is enabled for purposes of website accessibility

3 Healthcare Stocks That Actually Gained Ground Last Week

By Todd Campbell – Jan 20, 2016 at 4:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite a tumbling tape, shares in these three healthcare companies rallied.

Image source: Flickr user

Despite the industry-moving J.P. Morgan Healthcare Conference being held earlier this month, the Healthcare Select Sector SPDR ETF (XLV -0.84%) has dropped more than 7% this year, including a 1.7% tumble last week. The sell-off took most healthcare stocks lower, however, shares in these three healthcare stocks bucked the trend and traded up. Here's why.

No. 1: AbbVie (ABBV -0.36%): Up 4.1%
After forecasting that sales of its top seller, Humira, would keep growing, shares in AbbVie jumped over 4% last week.

Previously, investors have been nervous about AbbVie's future because the company generates more than 60% its sales from Humira (the drug hauls in about $14 billion per year), and Humira's composition of matter patent expires at the end of this year.

The company's outlook, however, puts some investor worries to rest because AbbVie thinks remaining manufacturing and dosing patents could prevent biosimilars from eating into Humira's market share for a few more years. As a result, management predicts Humira sales will increase to $18 billion in 2020.

If Humira hits that sales target, AbbVie believes its total sales could reach $37 billion that year (up from around $24 billion in 2015), and that prospect makes AbbVie shares far more intriguing than they were before.

No. 2: Intuitive Surgical (ISRG -2.51%) -- up 3.8%
At the J.P. Morgan conference, the maker of the Da Vinci surgical system reported that its fourth-quarter sales grew 12% year over year to $677 million, and that those sales resulted in full-year revenue growing 16% to $325 million.

Intuitive Surgical also said the number of surgical procedures conducted using the Da Vinci system increased by 14%, and that procedure growth in 2016 is forecast at between 9% and 12%.

Based on last week's rally, it appears investors think a healthy forecast for procedure growth and benefits tied to a larger installed number of systems bode well for sales of consumables. If so, Intuitive Surgical shares could benefit from a natural profit tailwind that insulates it against market risk.

No. 3: Anthem (ELV -1.30%) -- up 2.16%
The second largest national health insurer offered insight into its financials at the J.P. Morgan conference that suggest it's doing a better job at managing the profit headwinds associated with Obamacare enrollment that are plaguing competitors, including UnitedHealth Group.

The company will officially report its fourth-quarter financials on January 27, and when it does, management expects to deliver adjusted EPS of $10.16 for 2015 (handsomely ahead of its early 2015 predictions for above $9.70) and importantly, Anthem thinks adjusted EPS will climb to an adjusted $10.80 in 2016.

That's a pretty rosy forecast considering that profit worries at UnitedHealth have its management questioning whether or not it will continue to participate in the Obamacare marketplaces. Regardless, Anthem has a history of under-promising, so its 2016 forecast could end up proving to be a bit light; especially if it can wrestle savings from its ongoing dispute with its pharmacy benefit manager Express Scripts. According to Anthem, Express Scripts may owe it up to $3 billion in drug discounts -- a contention Express Scripts disputes. Nevertheless, a healthy forecast for earnings upside and potential benefits tied to its pending acquisition of Cigna (which could clear antitrust regulators and close this year) has investors increasingly hopeful. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Express Scripts and Intuitive Surgical. The Motley Fool recommends Anthem and UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

UnitedHealth Group Stock Quote
UnitedHealth Group
$521.56 (-0.31%) $-1.61
Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
Intuitive Surgical Stock Quote
Intuitive Surgical
$196.49 (-2.51%) $-5.05
Cigna Corp. Stock Quote
Cigna Corp.
Elevance Health Inc. Stock Quote
Elevance Health Inc.
$472.99 (-1.30%) $-6.24
AbbVie Stock Quote
$141.49 (-0.36%) $0.51
Health Care SPDR Stock Quote
Health Care SPDR
$125.41 (-0.84%) $-1.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.